- Business
- Childbirth & Education
- Legal Formalities
- Motoring
- Other
- Pensions & Benefits
- Property & Accommodation
- Taxes
- Airports and Airlines Spain
- Paramount Theme Park Murcia Spain
- Corvera International Airport Murcia Spain
- Join us for Tea on the Terrace
- When Expat Eyes Are Smiling
- Meet Wincham at The Homes, Gardens & Lifestyle Show, Calpe
- QROPS 2014
- Spain Increases IHT in Valencia & Murcia
- Removals to Spain v Exports from Spain
- The Charm of Seville
- Gibraltar Relations
- Retiro Park : Madrid
- Community Insurance in Spain
- Calendar Girls
- Considerations when Insuring your Boat in Spain
- QROPS – HMRC Introduces changes that create havoc in the market place
- QROPS – All Change From April 2012
- Liva & Laia : 15th November
Health Minister Trinidad Jimenez said Spain was already negotiating with the producers of the H1N1 vaccine to return excess stock, after those considered at high-risk from the new flu virus were not forthcoming, even after an extensive campaign.
"We are speaking with the pharmaceutical companies about returning unused vaccines", specialist news service APM Health Europe quoted her as saying earlier today ."The contracts signed with the companies from which we acquired the vaccines included clauses which allow the return of unused vaccines to the companies so they can be distributed to other countries," Jimenez added.
Germany also ordered 50 million doses of H1N1 vaccine from Glaxo, while Spain bought 22 million doses from Novartis , 14.7 million from Glaxo and 400,000 from Sanofi-Aventis.
Market Analysts reported how revenue generated from swine flu vaccines were expected to amount to $600 million for Novartis, 2.2 billion pounds sterling ($3.6 billion) for Glaxo and 750 million euros ($1.1 billion) for Sanofi for the last quarter of 2009 and first three months of 2010.
Officials at the various drugs manufacturing countries have not responded to the statements and neither were available for comment.